A Clinical Study to Evaluate the Efficacy and Safety of MK0633 in Patients With Atherosclerosis
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2014
At a glance
- Drugs Setileuton (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 27 Dec 2007 The expected completion date for this trial is now 1 Apr 2008.
- 29 Jan 2007 New trial record.